Corvus Pharmaceuticals (CRVS) News Today → The only AI company you should be looking at (From Behind the Markets) (Ad) Free CRVS Stock Alerts $1.90 0.00 (0.00%) (As of 03/18/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCorvus Pharmaceuticals (CRVS) Set to Announce Quarterly Earnings on Tuesdaymarketbeat.com - March 18 at 7:39 AMCRVS Apr 2024 4.000 putfinance.yahoo.com - March 16 at 3:41 PMCorvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024globenewswire.com - March 13 at 4:02 PMFinancial Review: Anebulo Pharmaceuticals (NASDAQ:ANEB) vs. Corvus Pharmaceuticals (NASDAQ:CRVS)americanbankingnews.com - March 10 at 2:16 AMWe Think Corvus Pharmaceuticals (NASDAQ:CRVS) Needs To Drive Business Growth Carefullyfinance.yahoo.com - March 9 at 1:52 PMCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest Down 8.0% in Februarymarketbeat.com - March 4 at 11:57 AMCRVS Mar 2024 3.000 putfinance.yahoo.com - February 17 at 7:36 AMCorvus Edges up on Disclosing Datamsn.com - February 12 at 6:33 PMCorvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Upfinance.yahoo.com - February 12 at 1:33 PMCorvus Pharmaceuticals Shares Rise on Orphan Drug Designationmarketwatch.com - February 8 at 6:17 PMCorvus lymphoma drug gets FDA orphan drug statusmsn.com - February 8 at 6:17 PMCorvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphomafinance.yahoo.com - February 8 at 6:17 PMCorvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officerfinance.yahoo.com - February 6 at 9:12 PMCorvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchellfinance.yahoo.com - January 23 at 7:04 PMIndividual investors in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) are its biggest bettors, and their bets paid off as stock gained 20% last weekfinance.yahoo.com - January 5 at 9:48 AMMaintaining Hold Rating on Corvus Pharmaceuticals Amid Steady but Unspectacular Clinical Progressmarkets.businessinsider.com - December 13 at 11:15 PMAre Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?msn.com - December 7 at 3:48 PMIs Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year?finance.yahoo.com - November 21 at 12:34 PMCorvus Pharmaceuticals Inc CRVSmorningstar.com - November 9 at 8:39 AMCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 8 at 2:58 PMQ3 2023 Corvus Pharmaceuticals Inc Earnings Callfinance.yahoo.com - November 8 at 9:57 AMCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 7 at 5:35 PMCorvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Expositionfinance.yahoo.com - November 2 at 10:24 AMCorvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseasesfinance.yahoo.com - November 1 at 11:19 PMCorvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023finance.yahoo.com - October 31 at 8:25 PMHere's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situationfinance.yahoo.com - October 1 at 10:16 AMAnalysts Conflicted on These Healthcare Names: Bioxcel Therapeutics (BTAI), Arcutis Biotherapeutics (ARQT) and Corvus Pharmaceuticals (CRVS)markets.businessinsider.com - September 12 at 1:42 PMCorvus Pharmaceuticals (NASDAQ: CRVS)fool.com - September 8 at 8:31 PMCantor Fitzgerald Reiterates Corvus Pharmaceuticals (CRVS) Overweight Recommendationmsn.com - September 7 at 7:18 PMCorvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDAfinance.yahoo.com - September 6 at 4:23 PMCorvus Pharmaceuticals Eyes Expansion Of Blood Cancer Therapy but Resource Limitations Pose Challenge: Oppenheimermarkets.businessinsider.com - August 18 at 4:38 PMCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) to Post FY2023 Earnings of ($0.50) Per Share, Cantor Fitzgerald Forecastsmarketbeat.com - August 14 at 3:51 AMCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Resultsfinance.yahoo.com - August 8 at 7:44 PMCircling Back On Corvus Pharmaceuticalsmsn.com - August 1 at 5:09 PMCorvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023finance.yahoo.com - August 1 at 5:09 PMCorvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)finance.yahoo.com - July 6 at 2:10 PMCorvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conferencefinance.yahoo.com - June 29 at 9:08 AMCorvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conferencefinance.yahoo.com - June 29 at 9:08 AMAnalysts Conflicted on These Healthcare Names: Cue Biopharma (CUE) and Corvus Pharmaceuticals (CRVS)markets.businessinsider.com - June 15 at 6:00 PMAldeyra, Bioventus top healthcare gainers; Mersana, Bone Biologics among losersseekingalpha.com - June 15 at 12:59 PMIndividual investors among Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) largest shareholders, saw gain in holdings value after stock jumped 23% last weekfinance.yahoo.com - June 4 at 1:08 PMCorvus Pharmaceuticals to Present at the Jefferies Healthcare Conferencefinance.yahoo.com - May 31 at 12:21 PMLadenburg Thalmann Maintains Corvus Pharmaceuticals (CRVS) Buy Recommendationmsn.com - May 30 at 4:17 PMIs Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?finance.yahoo.com - May 26 at 1:52 PMCorvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphomafinance.yahoo.com - May 17 at 9:19 AMCorvus Pharmaceuticals: Targeting $1 Billion/Year U.S. T-Cell Lymphoma Marketseekingalpha.com - May 12 at 6:35 PMCorvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Whyfinance.yahoo.com - May 12 at 1:35 PMCorvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Resultsfinanznachrichten.de - May 10 at 8:04 PMWhy Are Corvus Pharmaceuticals Trading Higher Todaybenzinga.com - May 10 at 3:02 PMCantor Fitzgerald Maintains Corvus Pharmaceuticals (CRVS) Overweight Recommendationmsn.com - May 9 at 7:23 PM Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address The only AI company you should be looking at (Ad)This is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse. Get the stock ticker here >>> CRVS Media Mentions By Week CRVS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRVS News Sentiment▼0.650.63▲Average Medical News Sentiment CRVS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRVS Articles This Week▼41▲CRVS Articles Average Week Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Annovis Bio News CervoMed News Carisma Therapeutics News Vaxxinity News Anixa Biosciences News Assertio News Cartesian Therapeutics News Clearside Biomedical News Chimerix News Sagimet Biosciences News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRVS) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportThe world’s greatest investmentPorter & CompanyMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.